Who can use Agamree(Vamorolone)?

It is indicated for the treatment of Duchenne Muscular Dystrophy (DMD) in patients aged 2 years and older.

Related Columns

Vamorolone(Agamree)

Duchenne muscular dystrophy (DMD) in patients aged 2 years and older.

WeChat Scan
Free Inquiry

Agamree(vamorolone): Clinical Uses, Recommended Dosage, Potential Side Effects

The package insert of Agamree provides comprehensive information on the use of the medication, including its indications, administration methods, and precautions. This article will conduct an in-depth...

Agamree (vamorolone): indications, dosage and precautions

To ensure the correct use of Agamree, reading the drug package insert is crucial. This article will explain how to use the medication correctly in accordance with the information in the package insert...

What is Agamree medicine

Agamree is an innovative glucocorticoid drug primarily composed of Vamorolone, developed by Santhera Pharmaceuticals in Switzerland. This drug is specifically designed to treat Duchenne muscular dystr...

FDA approves Agamree (vamorolone) for the treatment of Duchenne muscular dystrophy

Agamree (vamorolone) is the first differentiated glucocorticoid drug approved by the US FDA, designed for patients with Duchenne muscular dystrophy (DMD) aged 4 years and above. The drug balances anti...

Agamree's International approval and price information

Agamree (vamoxone) is the first innovative glucocorticoid approved for the treatment of Duchenne muscular dystrophy (DMD). Its global launch process has covered many countries. Understanding its launc...